Somatostatin Receptor Peptide Ligands Stability and Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current somatostatin analogs have limited efficacy due to their restricted interaction with somatostatin receptors sstr1, sstr3, and sstr4, and their short stability in blood, necessitating continuous infusion and limiting their clinical applications.
Innovation Solution
Modification of somatostatin peptides with non-natural or derivatized amino acids, such as substituting phenylalanine with aromatic synthetic amino acids, derivatizing the lysine side chain, or substituting cysteines with allylglycines, enhances stability in serum and gastric fluid and maintains or improves interaction with all five somatostatin receptors (sstr1 to sstr5).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If somatostatin analogs are developed to increase stability against enzymatic degradation, then stability in blood is improved, but interaction with certain somatostatin receptors (sstr1, sstr3, sstr4) is limited or lost
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (1, 2, 3, 6, 7, 8, 11, 12, 13, 14) of the somatostatin analog structure. These modifications include substituting amino acids with different side chain properties (aromatic, aliphatic, cyclic, charged, neutral) to optimize both stability and receptor binding affinity across all five sstr subtypes
Solution Approach 2:
The patent creates composite peptide structures by combining modified amino acid residues with the core somatostatin cyclic hexapeptide framework. Specific combinations of modified residues at different positions are tested to achieve a composite structure that simultaneously provides enzymatic stability and broad receptor subtype coverage, resulting in analogs with improved pharmacological profiles
2Reliability
If somatostatin is used for treatment, then therapeutic effect is achieved, but continuous endovenous infusion is necessary due to short half-life
Solution Approach 1:
The patent develops analogs with extended half-life by incorporating amino acid modifications that increase resistance to enzymatic degradation. This allows the drug to maintain therapeutic levels for longer periods, potentially enabling less frequent administration than continuous infusion, thus improving ease of operation while maintaining reliability
3Stability of the object's composition
If existing somatostatin analogs are used, then stability is improved, but clinical applications are limited due to restricted receptor interaction
Solution Approach 1:
The patent designs somatostatin analogs with universal binding capability across all five somatostatin receptor subtypes (sstr1-sstr5). By carefully selecting amino acid modifications at key positions, the analogs achieve simultaneous high affinity and selectivity for multiple receptor subtypes, thereby expanding clinical applicability to pathologies expressing any of these receptors while maintaining improved stability
Data Source
AI summary
The invention relates to peptide derivatives of general formula (I), their stereoisomers, mixtures thereof and/or their pharmaceutically acceptable salts, a method of obtaining them, pharmaceutical compositions containing them and the use thereof for the treatment, prevention and/or diagnosis of those conditions, disorders and/or pathologies in which the sstrl, sstr2, sstr3, sstr4 and/or sstr5 somatostatin receptors are expressed.